newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other seriou